GSK pledges further China investment after fine

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) has pledged to "regain the trust of the Chinese people" by making further commitments and investment in China in the wake of executive convictions and a corporate fine for bribery.

The pharma said it would attempt to become a "model of reform" for the China healthcare industry by continuing its scientific investment in the country, developing new medicines and vaccines for diseases prevalent in China, and increasing access to its products in city and rural areas through expansion of local production and price flexibility. ...